Why Oncology Analytics?
Over the past five years, U.S. anti-cancer drug costs have increased to $50B annually, driven primarily by availability and favorable reimbursement of new medicines. By 2021, global cancer drugs expenditures are expected to exceed $147B annually.
The Oncology Landscape
As cancer treatment options expand and costs continue to rise, health plans, providers and patients face a collective challenge when trying to determine the best course of treatment.
Why Oncology Analytics?
Evidence Based. Patient First.
Oncology Analytics believes that when building the optimal treatment plan, cost and quality are not mutually exclusive and that doing the “right thing” and putting the patient in a position to achieve the best possible outcome requires a consistent process for evaluating the efficacy, toxicity, and costs of treatment options.
Oncology Analytics understands the complexity involved in the management of cancer treatment options caused by the rapid pace of research and new drug introductions that is changing the oncology landscape on a daily basis. We are committed to the ongoing review and analysis of oncology treatments, their outcomes, and adverse effects to ensure that all cancer treatment recommendations provide the patient with the opportunity to achieve the best possible outcome.